Skyline’s novel products are drawn from three major therapeutic categories: pain control, infectious diseases and cardiovascular diseases. Managing illness in these categories is critical to a veterinarian’s practice and the health of their patients; they represent more than 60% of the prescriptions written by small animal veterinarians.
We understand what challenges veterinarians face and how to bring the right solutions to the veterinary market.
We’re opening the doors to human medical advancements and innovating those solutions in formulations that are optimized for veterinary patients.
Partnering with companies to apply novel delivery technologies to partners’ actives in selected high-value animal markets.
Innovation is the process of transforming new inventions by improving them to meet practical applications. Skyline Vet Pharma is harnessing the medical advancements of human medicine and innovating these products for optimal use in veterinary patients. This strategy reduces the timeline and risk associated with obtaining FDA/CVM approval for new products and results in a rich pipeline of products optimally designed for veterinary patients.
The Skyline team brings over 60 years of experience to the development of a unique and strong portfolio of products needed to solve some of today’s toughest problems in veterinary medicine. We understand the everyday treatment challenges of the veterinarian and how to streamline the development and registration process of bringing novel proprietary solutions to the clinic.